To determine which of the 86 amino acids in the Tat protein of human inmunodeficiency virus type 1 (HIV-1) are important for transactivation, peptides from Tat were synthesized and their activity was measured in cells containing a chloramphenicol acetyltransferase reporter gene under control of the HIV long terminal repeat promoter.
prepare pure peptides in good yield by using fluoren-9-ylmethoxycarbonyl (Fmoc) chemistry. A peptide containing residues 1-58 had 5-10% the activity of full-length Tat. Deleting 4 amino acids from the N terminus of this peptide further reduced activity, while peptides with more extensive N-terminal deletions and peptides missing the basic region at the C terminus had no detectable activity. A peptide previously reported to transactivate, Tat-(37-62), was completely inactive in our assays. Inactive peptides were also tested as possible inhibitors of transactivation. Tat-(21-38), which contains the cysteine-rich region and can form heterodimers with intact Tat in vitro, showed inhibition at high peptide concentrations. However, this effect was not specific for Tat or for the HIV promoter, since the peptide also inhibited expression from the simian virus 40 early promoter.
The Tat protein from human immunodeficiency virus (HIV) is a potent viral transactivator (1) that is essential for viral replication (2, 3) . Although the precise mechanism of transactivation remains unclear, Tat may cause accumulation of mRNA by increasing the rate of transcription from the long terminal repeat (LTR) promoter (4, 5) , by acting as a transcriptional antiterminator (6) , or by stabilizing viral mRNAs (7) (8) (9) (10) . Tat may also increase translational efficiency (7) (8) (9) (10) (11) (12) . A region of about 40 base pairs just 3' to the start of transcription [the transactivation response (TAR) site] is necessary for transactivation by .
The Tat protein is 86 amino acids long and contains a highly basic region (with 2 lysines and 6 arginines in 9 residues) and a cysteine-rich region (with 7 cysteines in 16 residues) (16, 17) . The basic region is important for nuclear localization (18, 19) . The cysteine-rich region mediates the formation of metal-linked dimers in vitro (20) , although it is not known whether the metal-linked dimer is important for transactivation. An 18-amino acid peptide containing just the cysteinerich region of Tat can also form metal-linked dimers and can form heterodimers with intact Tat in vitro (21) . It was suggested that, ifdimerization is essential for transactivation, this peptide might inhibit Tat activity by forming inactive heterodimers (20, 21) .
It is now possible to directly measure the activity of Tat peptides and to test whether peptides can inhibit transactivation. Assays have recently been developed that use a procedure known as "scrape-loading" to introduce Tat into tissue culture cells that contain the HIV-1 promoter linked to a reporter gene (22, 23) . It is believed that this procedure transiently damages cell membranes, allowing molecules in the medium to enter the cytoplasm. During development of the scrape-loading assay, it was also found that Tat could be taken up by cells simply growing in tissue culture and could enter the nucleus and transactivate the HIV-1 promoter (22) . Uptake and transactivation could be stimulated as much as 1000-fold with lysosomotrophic agents such as chloroquine, which apparently prevent proteolysis of Tat (22) . We use these assays to measure the activity of Tat peptides synthesized by fluoren-9-ylmethoxycarbonyl (Fmoc) chemistry and show that the N-terminal region, the cysteine-rich region, and the basic region are all necessary for transactivation. We also show that peptides that are capable of forming heterodimers with intact Tat in vitro do not specifically inhibit Tat 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tems protein sequencer; P. Matsudaira, Whitehead Institute) and found to be correct. Tat-(37-62) was also analyzed by fast-atom bombardment (FAB) mass spectrometry (T. D. Williams and J. A. Leary, University of California, Berkeley). A VG ZAB2-EQ instrument was used with a primary FAB beam energy of 30-keV cesium ions (1 eV = 1.602 x 10-9 J) at 3-MtA emission current. Peptide was dissolved in dilute acetic acid before addition to the 3-nitrobenzyl alcohol liquid matrix, and mass assignments were made by calibration against cesium iodide cluster ions. The measured molecular weight of the MH' ion was 3060 (calculated, 3059.8).
Tat-(1-72) and Tat-(1-86) bacterial proteins were purified as described (20, 22) . Chymotryptic fragments of Tat (residues 1-47 and 48-86) were prepared by partial proteolysis of Tat-(1-86) with chymotrypsin (20) followed by C4 HPLC purification.
Transactivation Assays. Transactivation was assayed by introducing Tat proteins or peptides into HeLa cells containing an integrated HIV-1 LTR-chloramphenicol acetyltransferase (CAT) gene construct (HL3T1 cells; ref. 25) . For most experiments, cells (50-70% confluent) were scrape-loaded with peptide in 25-mm wells in the presence of 100 ,uM chloroquine (see ref. 22) . The combination of scrape-loading and chloroquine treatment gives about 10-fold higher transactivation than either method alone. Cells were incubated at 370C for 24 hr and assayed for CAT activity (26) . Some plasmids (pHIV-CAT, pSV2tat72, or pSV2cat) were transiently transfected into HeLa cells by lipofection for 4 hr (27) before introduction of proteins or peptides. In these cases, CAT activity was assayed 24 hr after peptide treatment. All cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
RESULTS
Peptide Synthesis. To determine which regions of the 86-amino acid Tat protein are important for transactivation, several Tat fragments were synthesized using Fmoc chemistry (Fig. 1) . Peptides corresponding to Tat residues 1-58, 5-58, 10-58, 15-58, 21-58, and 38-58 were synthesized by starting with the C-terminal Pro-58 and removing aliquots of the resin at appropriate points in the synthesis. Similarly, peptides corresponding to residues 1-38, 4-38, 10-38, 15-38, and 21-38 were synthesized by starting with the C-terminal Phe-38. An additional peptide containing residues 37-62 was synthesized. After cleavage and deprotection, each peptide was reduced with 0.5 M dithiothreitol, purified by reversephase HPLC (to >90%o purity by HPLC analysis), and characterized by amino acid analysis. The identity of Tat-(37-62) was further confirmed by peptide sequencing and FAB mass spectrometry. The n-58 series of peptides was synthesized twice, and the final products from each synthesis were identical. Overall yields of Tat-(1-58), -(1-38), and -(37-62) were estimated to be 20%, 30%, and 60%, respectively.
Ultraviolet absorption spectroscopy was used to estimate the amount of each peptide and to monitor metal binding to the cysteine-rich region (residues 22-37) (20, 21) . Peptides containing the cysteine-rich region were titrated with CdCl2 and showed the expected stoichiometry of 2 metal ions per peptide monomer (refs. 20 and 21; data not shown). The reduced Tat peptides were also analyzed by polyacrylamide gel electrophoresis under nondenaturing conditions (Fig. 2) . Each peptide showed the expected migration based on size and charge, and, as seen with the intact protein (20) , peptides that contained the cysteine-rich region oxidized to form Tat oligomers during electrophoresis.
Activity of Tat Peptides. Each Tat peptide was tested for its ability to transactivate the HIV-1 promoter. Peptides were scrape-loaded into HeLa cells containing an integrated LTR-CAT construct (HL3T1 cells) (22) . Cells were also incubated with chloroquine, which inhibits Tat proteolysis (22) and increases the signal about 10-fold. Bacterially synthesized Tat-(1-86) and Tat-(1-72) transactivated the HIV-1 promoter at least 350-fold (Fig. 3) . Of the synthetic peptides with the C terminus at residue 58, Tat-(1-58) showed reasonable transactivation (about 35-fold; Fig. 3 ). Tat-(5-58) also showed some transactivation (about 10-fold), but no other peptide had significant activity. No activity was seen with any peptide ending with its C terminus at Phe-38. Chymotryptic fragments containing residues 1-47 or 48-86 were also assayed and showed no transactivation (data not shown). These results suggest that the N-terminal region, the cysteine-rich (Fig. 3) . To test directly whether the Tat-(37-62)-peptide has transactivation activity, we resynthesized Tat-(37-62) and confirmed its identity by amino acid analysis, peptide sequencing, and FAB mass spectrometry (see Materials and Methods). Tat-(37-62) was introduced into HL3T1 cells by (i) adding peptide to the medium, (ii) scrape-loading, (iii) incubating cells with peptide and chloroquine, or (iv) scrape-loading in the presence of chloroquine. The peptide had no detectable activity, even at molar concentrations 100-fold higher than Tat-(1-72) (Fig. 4) . Cellular uptake of radioiodinated Tat-(37-62) was also measured (see ref. 22 ). The amount of peptide taken up from the medium was about 10-fold less than for Tat-(1-72), but the amount of internalized peptide could be increased by scrapeloading (data not shown). Thus, even though the Tat-(37-62)-peptide was present inside cells, it showed no transactivation activity.
Inhibition of Transactivation. It was shown previously that Tat could form metal-linked dimers in vitro and that an 18-residue peptide containing just the cysteine-rich region (residues 21-38) could mimic Tat dimerization (20, 21) . The peptide also formed heterodimers with the intact protein, suggesting that if the dimer is important for Tat transactivation, Tat-(21-38) might inhibit the activity of Tat by forming inactive heterodimers (21 (27) . One milliliter of fresh medium was added, and Tat-(21-38) was scrape-loaded in the presence of chloroquine. CAT activity was determined 24 hr after scrape-loading.
10-58, 15-58, 21-58, 38-58, and 1-38) was also tested but none showed any inhibition at 20 Ag/ml.
DISCUSSION
A quantitative analysis of synthetic HIV-1 Tat peptides and bacterially produced Tat proteins has shown that most of the Tat sequence is required to achieve high levels of transactivation. This analysis was made possible by recent advances in Fmoc chemistry that allow synthesis of the complex cysteine-and arginine-rich sequences found in Tat. The major advantages of Fmoc chemistry for such sequences are the relatively mild cleavage conditions, which help minimize irreversible cysteine modifications, and the complete deprotection of cysteine and arginine side chains achieved by using trityl and pentamethylchroman-6-sulfonyl protecting groups, respectively.
The full-length Tat protein is 86 amino acids long and is encoded by two exons; the N-terminal 72 residues are encoded by the first exon and the C-terminal 14 residues are encoded by the second exon. In the unspliced mRNA, there is a highly conserved termination codon immediately after residue 72, allowing translation of just the 72-amino acid exon. The 72-and 86-amino acid proteins have similar activities (Fig. 3) , consistent with previous studies suggesting that the second exon is dispensable for activity (8, 9, 17) . A synthetic peptide corresponding to Tat residues 1-58 has 5-10% the activity of the 1-86 or 1-72 bacterial protein (Fig.  3) , suggesting that residues between 58 and 72 also contribute to transactivation. Other studies have shown that a Tat deletion mutant containing residues 1-60 and Tat fusion proteins containing residues 1-56 or 1-58 have somewhat reduced activity (9, 29, 30) .
Deleting further from the C terminus, to residue 47 in the chymotryptic fragment or to residue 38 in the synthetic peptides, completely eliminates transactivation. These peptides lack the basic region of Tat, which seems to be important for nuclear localization (18, 19) , and mutations in this region have been shown to reduce transactivation (18, 19) . Residues at the N terminus are also important for activity; a peptide with the first 4 amino acids deleted [Tat-(5-58)] has reduced activity, and peptides with more extensive deletions [Tat-(10-58), -(15-58), and -(21-58)] are completely inactive (Fig. 3) . Garcia et al. (29) reported that an N-terminal deletion mutant containing residues 10-86 also had little activity. Tat-(21-38), a small peptide containing just the cysteine-rich region, had no activity.
It has been reported that a synthetic peptide containing only Tat residues 37-62 has significant transactivation activity (28 (20, 21) . To resolve the apparent discrepancy, we resynthesized Tat-(37-62) and found that it has no detectable activity under four different assay conditions (Fig. 4) . We cannot explain the difference in results.
Tat has been shown to form metal-linked dimers in vitro, with four metal ions bridging the cysteine-rich regions from each monomer (20) . A peptide containing just the cysteinerich region [Tat-(21-38)] formed heterodimers with intact Tat in vitro (21) , leading to the suggestion that this peptide might inhibit transactivation if dimerization is important for activity. Tat-(21-38) was found to inhibit Tat transactivation at high peptide concentrations, but the effect was nonspecific since it also blocked expression from the simian virus 40 early promoter at similar concentrations (Fig. 5 ). This inhibition may be caused by the seven peptide thiol groups, since other thiol reagents, such as 2-mercaptoethanol or dithiothreitol, can inhibit cell growth (A.D.F., unpublished data). Other Tat peptides were also tested for inhibition and no specific effects were seen. Although there are many possible explanations for why these peptides do not show trans-dominant inhibition in our assays, it seems unlikely that they can be used to specifically block Tat function in vivo.
Note Added in Proof. In a recent paper (32) , it was suggested that Tat peptides may be unstable during the time course of our assays. However, it has been shown (22) that transactivation can be easily detected after only 1 hr of Tat treatment (35-fold). Transactivation increases to more than 1000-fold after 8 hr and reaches a plateau by 24 hr. It seems unlikely that treatment times can explain any differences in the activity of Tat-(37-62) or other Tat peptides.
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